Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on ESPR. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald began coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.25.

Esperion Therapeutics Stock Performance

Shares of Esperion Therapeutics stock opened at $2.10 on Thursday. The company has a market capitalization of $413.77 million, a PE ratio of -3.28 and a beta of 1.03. The company has a 50-day simple moving average of $2.46 and a two-hundred day simple moving average of $2.17. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $51.63 million for the quarter, compared to analysts’ expectations of $55.44 million. During the same period in the previous year, the business posted ($0.37) EPS. On average, equities analysts predict that Esperion Therapeutics will post -0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at $606,000. Anson Funds Management LP acquired a new position in Esperion Therapeutics during the third quarter valued at $540,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Esperion Therapeutics by 71.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 295,378 shares during the last quarter. Wellington Management Group LLP grew its position in Esperion Therapeutics by 66.8% during the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after purchasing an additional 241,512 shares during the period. Finally, Wasatch Advisors LP raised its stake in shares of Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after buying an additional 6,483,070 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.